长城基金梁福睿：2026年创新药行情值得期待

Core Viewpoint - The pharmaceutical industry is transitioning from a focus on model innovation to breakthroughs in technological innovation, reshaping investment logic [1][4]. Group 1: Current Industry Trends - The pharmaceutical sector is entering a critical period characterized by innovative breakthroughs and technological integration [1][4]. - There is a shift from model-based innovation to technological breakthroughs, impacting both innovative drugs and devices [1][4]. - Companies with global capabilities that can iteratively influence existing treatment methods are expected to develop through their own innovations [1][4]. Group 2: Future Outlook for 2026 - The outlook for innovative drugs in 2026 remains positive, with expectations of both Beta and Alpha growth, indicating a dual resonance [2][5]. - The development of innovative drugs in China is expected to resonate with secondary market stock prices, with a strong correlation emerging from mid-2025 [2][5]. - Significant global Phase III clinical trials and impactful clinical data releases in 2026 are anticipated to alleviate market concerns, suggesting potential for increased global value of innovative drugs [2][5]. - The overall liquidity environment in 2026 is expected to be favorable, supporting the growth of innovative drugs alongside industry trends and Alpha changes [2][5].